Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma (Nasdaq: CBIO) announced inducement option grants to two non-executive employees totaling 12,525 ordinary shares under its 2025 Employment Inducement Incentive Award Plan, as amended.

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) announced inducement option grants to two non-executive employees totaling 12,525 ordinary shares under its 2025 Employment Inducement Incentive Award Plan, as amended. Grants were approved April 23, 2026, with a 10-year term and an exercise price of $25.70.

Options vest 25% after one year then 1/48th monthly thereafter, subject to continuous service and plan terms.

Argus Apr 27 session

+1.41% close to close 0.5x rel. volume Open Argus

Details

News Market Reaction – CBIO

On Apr 27, the first trading day after this news, CBIO closed 1.41% above the previous close.

Data tracked by StockTitan Argus for the Apr 27 session.

Key Figures

Inducement option shares: 12,525 shares Number of employees: 2 employees Option term: 10 years +5 more

Inducement option shares

12,525 shares

Options granted to two non‑executive employees under 2025 Inducement Plan

Number of employees

2 employees

Recipients of inducement option awards

Option term

10 years

Duration of granted stock options

Exercise price

$25.70

Closing price on Nasdaq on April 23, 2026

Initial vesting fraction

1/4 of shares

Vests on first anniversary of each employee’s start date

Ongoing vesting rate

1/48 of shares monthly

Monthly vesting after first anniversary, contingent on continuous service

Plan year

2025

Crescent Biopharma Employment Inducement Incentive Award Plan

Price change before news

-4.74%

CBIO 24‑hour move prior to this announcement

Historical Context

5 past events · Latest: Mar 27

5 events

1. Mar 27

   Inducement awards

   24h Move

   +9.6%

   Options for 35,325 shares granted to three non‑executive employees.

2. Mar 06

   Inducement awards

   24h Move

   -0.4%

   Inducement options for 45,675 shares to two non‑executive employees.

3. Feb 26

   Earnings and update

   24h Move

   -1.2%

   Q4 and 2025 results plus partnership, trial, and financing highlights.

4. Feb 23

   Conference participation

   24h Move

   -1.6%

   Planned presentations at two March 2026 investor conferences.

5. Feb 19

   Inducement awards

   24h Move

   +20.8%

   Inducement options totaling 24,600 shares to two employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

equity inducement awards, nasdaq listing rule 5635(c)(4), exercise price

3 terms

equity inducement awards financial

"options to purchase an aggregate of 12,525 shares ... as equity inducement awards under"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

nasdaq listing rule 5635(c)(4) regulatory

"material to each employee's acceptance of employment ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"a 10-year term and an exercise price equal to $25.70, the closing price per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 12,525 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on April 23, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $25.70, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on April 23, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma 

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. 

Contact

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Crescent Biopharma (CBIO) grant as inducement awards on April 23, 2026?

Crescent granted options to purchase an aggregate of 12,525 shares to two non-executive employees. According to the company, the grants were approved on April 23, 2026 and issued under the 2025 Employment Inducement Incentive Award Plan.

What exercise price and term apply to the CBIO inducement options granted April 23, 2026?

The options carry a $25.70 exercise price and a 10-year term. According to the company, $25.70 was the Nasdaq closing price on April 23, 2026 and sets the per‑share exercise price for the grants.

What is the vesting schedule for the Crescent Biopharma (CBIO) inducement option awards?

Options vest with 25% after one year and then 1/48th monthly thereafter. According to the company, vesting is subject to continuous service through each vesting date and the terms of the applicable option agreements.

Were the CBIO inducement awards tied to Nasdaq listing rules or employee hiring?

Yes. The grants were approved as inducement awards and were described as material to each employee’s acceptance of employment. According to the company, this conforms with Nasdaq Listing Rule 5635(c)(4) requirements for inducement grants.

Under which plan were Crescent Biopharma (CBIO) inducement options granted?

The options were granted under the 2025 Employment Inducement Incentive Award Plan, as amended. According to the company, each option is also subject to the specific terms and conditions of an individual option agreement covering the grant.

Who received the inducement option grants from Crescent Biopharma (CBIO)?

The grants were made to two non-executive employees as equity inducement awards. According to the company, the grants were material to each employee’s acceptance of employment with Crescent and were approved by the independent Compensation Committee.